LONDON, Nov 28 (Reuters Breakingviews) - German chemical distributor Brenntag (BNRGn.DE) is eyeing $5 billion U.S. rival Univar Solutions (UNVR.N). A deal would offer the $10 billion group scale in a fragmented market, and greater exposure to North America. But it also carries risks.
There’s good reason for more M&A in a sector that blends chemicals and transports them from manufacturers to customers like carmakers or drug companies. It’s still relatively fragmented, with the top six players accounting for just 12% of sales. A deal would offer synergies and scale, and give Brenntag more exposure to North America. That market may be more resilient to Europe’s energy crunch, and it made up nearly 70% of Univar sales in 2021.
If Chief Executive Christian Kohlpaintner pays $40 a share, a roughly 30% premium, he would value his quarry at $8.6 billion including debt. Assume cost savings of perhaps $500 million, and Brenntag would reap some $905 million of net operating profit after tax and synergies in 2023. That would deliver a comfortable 10% return on invested capital, in line with Univar’s cost of capital.
Still, the news sent Brenntag’s shares down some 9% on Monday. A deal would be bigger than the bolt-on transactions expected by investors and may require some equity issuance. Any mega-deal looks risky on the eve of a downturn. And given the healthier U.S. market, there’s a risk Brenntag gets stuck in a bidding war – or ends up overpaying. (By Neil Unmack)
Follow @Breakingviews on Twitter
(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)
Capital Calls - More concise insights on global finance:
Dr. Martens exposes fashion’s squeezed middle read more
A divided Fed hides behind fuzzy language read more
Foxconn is stuck between rock and hard place read more
ABB takes valid detour around hairy IPO markets read more
Italy’s Meloni will dodge EU collision on budget read more
Our Standards: The Thomson Reuters Trust Principles.